Clinical Trial Update: The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation [Phase 4]

View source ↗

Summary

Clinical trial update comparing 3 years vs 1 year of dual antiplatelet therapy after XINSORB bioresorbable scaffold implantation in a Phase 4 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Drugs mentioned

• XINSORB

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Cardiovascular Diseases | Phase 4 | Status: NOT_YET_RECRUITING